Journal Home
Search for

Volume 43, Issue 7, Pages 491-498 (November 2009)


View previous. 2 of 11 View next.

Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond

Roberto CiccocioppoaCorresponding Author Informationemail address, Donald R. Gehlertb, Andrey Ryabininc, Simranjit Kaurc, Andrea Cippitelliad, Annika Thorselld, Anh D. Lêe, Philip A. Hipskindb, Chafiq Hamdouchib, Jianliang Lub, Erik J. Hembreb, Jeffrey Cramerb, Min Songb, David McKinzieb, Michelle Morinb, Daina Economidoua, Serena Stopponia, Nazzareno Cannellaa, Simone Braconia, Marsida Kallupia, Giordano de Guglielmoa, Maurizio Massia, David T. Georged, Jody Gilmand, Jacqueline Hershd, Johannes T. Tauscherb, Stephen P. Huntf, Daniel Hommerd, Markus Heiligd

Received 30 March 2009; accepted 12 August 2009.

Abstract 

This article summarizes the proceedings of a symposium held at the conference on “Alcoholism and Stress: A Framework for Future Treatment Strategies” in Volterra, Italy, May 6–9, 2008. Chaired by Markus Heilig and Roberto Ciccocioppo, this symposium offered a forum for the presentation of recent data linking neuropetidergic neurotransmission to the regulation of different alcohol-related behaviors in animals and in humans. Dr. Donald Gehlert described the development of a new corticotrophin-releasing factor receptor 1 antagonist and showed its efficacy in reducing alcohol consumption and stress-induced relapse in different animal models of alcohol abuse. Dr. Andrey Ryabinin reviewed recent findings in his laboratory, indicating a role of the urocortin 1 receptor system in the regulation of alcohol intake. Dr. Annika Thorsell showed data supporting the significance of the neuropeptide Y receptor system in the modulation of behaviors associated with a history of ethanol intoxication. Dr. Roberto Ciccocioppo focused his presentation on the nociceptin/orphanin FQ (N/OFQ) receptors as treatment targets for alcoholism. Finally, Dr. Markus Heilig showed recent preclinical and clinical evidence suggesting that neurokinin 1 antagonism may represent a promising new treatment for alcoholism. Collectively, these investigators highlighted the significance of neuropeptidergic neurotransmission in the regulation of neurobiological mechanisms of alcohol addiction. Data also revealed the importance of these systems as treatment targets for the development of new medication for alcoholism.

a Department of Experimental Medicine and Public Health, University of Camerino, Via madonna delle Carceri, 62032 Camerino, Macerata, Italy

b Lilly Research Laboratories, Indianapolis, IN 46285, USA

c Department of Behavioral Neuroscience, Oregon Health and Sciences University, Portland, OR 97239, USA

d Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA

e Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario M5S 2S1, Canada

f Department of Anatomy and Developmental Biology, University College London, London WC1E 6BT, UK

Corresponding Author InformationCorresponding author. Tel.: +39-0737-403313; fax: +39-0737-630618.

PII: S0741-8329(09)00104-9

doi:10.1016/j.alcohol.2009.08.003


View previous. 2 of 11 View next.